Announcement on Subsidiary Obtaining Notice of Approval for Drug Clinical Trials
Release time:
2021-05-20
Securities Code: 600668 Securities Abbreviation: Jianfeng Group No: pro 2020-018
Zhejiang Jianfeng Group Co., Ltd.
Announcement on Subsidiaries Obtaining Notice of Approval for Drug Clinical Trials
The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assumes individual and joint responsibility for the truthfulness, accuracy and completeness of its contents .
Important Note:
- Company's approval notice for drug clinical trials will not have a significant impact on the company's recent operating results.
- Risk Warning: Due to the particularity of drug research and development, the pre-development of drugs and the long cycle and many links of products from development, clinical trials to production are susceptible to some uncertain factors, clinical trial progress, There are many uncertainties in the results and the future product market competition situation.
1. Summary
Recently, Zhejiang Jianfeng Yien Biotechnology Co., Ltd. (hereinafter referred to as "Jianfeng Yien") , , a holding subsidiary of Zhejiang Jianfeng Pharmaceutical Co., Ltd., the company's holding subsidiary, received the "Drug Clinical Trial Approval Notice" approved and issued by the State Food and Drug Administration, "JFAN-1001 Capsule, Notice No: 2020LP00246 " and "JFAN-1001 Capsules, Notification No: 2020LP00247 ". The relevant details are hereby announced as follows:
2. drug basic information content
drug name: JFAN-1001 capsule
English name: JFAN-1001Capsule
dosage form: capsule
application item: clinical research application
specification: 10mg , 30mg
registration classification: chemical drugs category
applicant: Zhejiang Jianfeng yien biotechnology co., ltd
approval conclusion: "according to the the People's Republic of China drug administration law and relevant regulations, after examination, 2020 6 February 7 accepted JFAN-1001 glue capsule meets the relevant requirements of drug registration and agrees to carry out clinical trials according to the submitted plan."
3. Drug Research and Development and Registration
JFAN-1001 is a new anti-tumor drug developed by Jianfeng Yien. The registration classification belongs to chemical drug 1 . Jianfeng Yien first submitted JFAN-1001 clinical trial application and was accepted on 2020 6 January 7 (acceptance numbers: CXHL2000255 , CXHL2000256 ). JFAN-1001 is a small molecule antineoplastic agent with indications for EGFR-T790M secondary mutation-positive locally advanced or metastatic non-squamous non-small cell lung cancer. As of the date of this announcement, the accumulated research and development expenses and technical investment of the project totaled about 4676.04 .03 million yuan.
Market Situation of Similar Drugs in 4.
Currently, targeted drugs for epidermal growth factor receptor (EGFR ) inhibitors listed in China include: the first generation EGFR inhibitors include gefitinib, erlotinib and icotinib; The second generation EGFR inhibitors include afatinib and dacotinib; the third generation EGFR inhibitor includes AstraZeneca's osimertinib, which was approved for listing in the United States on November 11, 2009, , , , and approved for listing in China on March 122, , 2017, . AstraZeneca global annual sales of osimertinib in 2019, , .7 billion (source: 2019# AstraZeneca Annual Financial Statement for 129), almetinib of Jiangsu Haosen Pharmaceutical Co., Ltd. was approved to be listed in China in January , March this year. The company's JFAN-1001 is the third generation EGFR inhibitor with the same target as osimertinib, at present, similar drugs in the clinical research stage include efitinib of Shanghai Alex pharmaceutical technology co., ltd., avetinib of Hangzhou essen pharmaceutical research co., ltd., Nanjing shenghe pharmaceutical co., ltd. SH-1028 , Jiangsu osaikang pharmaceutical co., ltd. ASK120067 , Jiangsu runxin biotechnology co., ltd. RX518 and many other enterprises. Approval Procedure for 5. Products to Be Listed Jianfeng Yien will conduct clinical trials according to the requirements of the Notice of Approval of Drug Clinical Trials. After the clinical trials are completed, production will be declared. Production and marketing can only be carried out after passing the review and approval of the State Food and Drug Administration and obtaining the approval documents for drug production. 6. Impact on Listed Companies and Risk Tips
The company's approval notice for drug clinical trials will not have a significant impact on the company's recent operating results. Due to the particularity of drug research and development, the pre-development of drugs and the long cycle and many links from development, clinical trials to production of products are easily affected by some uncertain factors. There are many uncertainties in the progress and results of clinical trials and the future product market competition situation. The company will be based on the progress of research and development in a timely manner to fulfill the obligations of information disclosure, so that the majority of investors pay attention to investment risks.
hereby announce
Zhejiang Jianfeng Group Co., Ltd.
Board of Directors August 19, 2020
More information
Spike Cable Enters South American Market
Recently, a batch of 2100-pair communication cables produced by Peak Cable Company for Venezuelan customers have been completed and will be shipped in cabinets. This is the company's first export business in the South American market. In recent years, under the general trend of "light in and copper out" in the domestic market, Jianfeng Cable Company has taken the initiative to open up foreign markets that still use copper-core communication cables. While making use of its own production advantages to actively cooperate with domestic industry and trade enterprises to carry out foreign trade processing of communication cables, it has made great efforts to expand its own export business through foreign trade platforms and participation in exhibitions. Since the beginning of this year, the cable company has overcome the adverse effects of the new coronary pneumonia epidemic, actively looking for foreign customers for business negotiations, and won orders from Vietnamese customers shortly after the resumption of work. It is understood that in all the export business of cable companies this year, self-operated export business has accounted for about half, and the export direction is mainly Southeast Asia. The successful completion of the Venezuelan customer orders for the future further development of Colombia, Argentina, Peru, Chile and other South American countries to lay a good foundation. (Hu Longgang, Huang Yuan)
2020
11-12
Daye peak "war epidemic" work was commended by Hubei Province, Huangshi City
Recently, Daye Peak Cement Company won the commendation of Hubei Provincial Federation of Industry and Commerce, Hubei General Chamber of Commerce, Huangshi City Federation of Industry and Commerce, Huangshi City Chamber of Commerce, Huangshi City People's Government Poverty Alleviation and Development Office and other relevant units for its outstanding achievements in the prevention and control of the new coronary pneumonia epidemic. Since the beginning of this year, in the face of the new coronary pneumonia epidemic, Daye Peak has fully implemented the important instructions of the municipal government on the prevention and control of the new coronary pneumonia epidemic and the decision-making and deployment of poverty alleviation, obeying the overall situation, not only donating money to the Daye Municipal People's Government for the first time to help prevent and control the epidemic, but also actively do a good job in the prevention and control of the internal epidemic, and to resume production, and earnestly implement the municipal party committee and municipal government on the response to the impact of the new coronary pneumonia epidemic to carry out "two help two help" and "three get one stable" work requirements, paired to help the surrounding rural part of the population has not been lifted out of poverty, to help poor areas to solve the problem of agricultural and sideline products sales, for the city's decisive fight against poverty to contribute. (Yang Huiping, Zhang Qingyu)
2020
11-12
Liu Haiping, Vice Mayor of Pu'er, went to Yunnan Jianfeng for investigation
On the morning of November 3, Liu Haiping, member of the standing Committee of the Pu'er Municipal CPC Committee and vice mayor of the municipal government, and responsible persons of relevant departments went to Yunnan Jianfeng cement Company for investigation and discussion with Zhou Jiping, general manager of Yunnan Jianfeng, and Fang Xuhua, deputy general manager, on such topics as improving the business environment of Pu'er City and the difficulties encountered in the production and operation of enterprises. During the exchange, Zhou Jiping reported on the production and operation of the company this year, as well as the impact of the new coronary pneumonia epidemic on the market and the difficulties encountered in the production and operation process. Liu Haiping fully affirmed the efforts and achievements made since the resumption of work and production in Yunnan Peak, and said that a good business environment is very important for economic development and enhancing the vitality of enterprises. The functional departments of Pu'er government at all levels will continue to optimize various tasks, improve work efficiency, and provide services and guarantees for the development of enterprises. Liu Haiping hopes that Yunnan Jianfeng, as a key enterprise and "benchmark enterprise" in Pu'er City, will play a pioneering and exemplary role and jointly promote the construction of the business environment in Pu'er City. (qi jianmei)
2020
11-12
On the afternoon of November 10, the Party committee of the group company held an enlarged meeting to learn the spirit of the Fifth Plenary Session of the 19th CPC Central Committee and make arrangements for the next step of study, publicity and implementation. At the meeting, Jiang Xiaomeng, Secretary of the Party committee and chairman of the group company, together with all members of the Party committee, members of the management team of the group company, heads of functional departments and some party members, studied the communique of the Fifth Plenary Session of the 19th CPC Central Committee and interpreted the spiritual points of the plenary session. Jiang Xiaomeng pointed out that the Fifth Plenary Session of the 19th Central Committee of the Communist Party of China, held in Beijing from October 26 to 29, is a very important meeting held at an important historical moment when the victory of building a moderately prosperous society in an all-round way is in sight and the new journey of building a modern socialist country in an all-round way is about to begin. It fully embodies the foresight of the Party Central Committee with Comrade Xi Jinping as the core in planning the future and the historical responsibility of carrying forward the past, and profoundly points out the guidelines, objectives, tasks, and strategic measures for China's development in the coming period. It is of great and far-reaching significance to mobilize and encourage the whole Party and the people of the whole country to continue to seize the important strategic opportunity period and promote the comprehensive construction of a socialist modern country. In response to the goals and some hot issues raised in the plenary communiqué, such as how to achieve the 2035 long-term goal, the key goals of economic and social development during the "14th Five-Year Plan" period, why the emphasis is on adhering to the party's overall leadership and strengthening the centralized and unified leadership of the party Central Committee. The main risks and challenges facing economic development in the next five years, how to achieve scientific and technological self-reliance, promote innovation, how to understand the construction, jiang Xiaomeng quoted the answers given by the leaders of relevant central ministries and commissions at the press conference of the plenary session. Jiang Xiaomeng emphasized that China's current development environment is facing profound and complex changes, and there are new developments and changes in opportunities and challenges. The guiding ideology and principles of economic and social development during the "14th Five-Year Plan" period proposed by the plenary session, and the economy during the "14th Five-Year Plan" period The main goals of social development will have a direct impact on the future development of our enterprises. Party organizations at all levels and all employees at the peak must study and study carefully, find the entry point and direction of work, make every effort to complete the annual work goals, and make preparations for the next year. The person in charge of the party organization of the company's overseas enterprises participated in the study through the video conference system. (this newspaper reporter)
2020
11-12
Zhou Zhou, executive vice governor of Qiandongnan Prefecture, sent a message to Huang Ping Jianfeng: fully promote the normalization of production and marketing to make new contributions to Huang Ping's overall well-off society. On October 27, Zhou Zhou, executive vice governor of Qiandongnan Prefecture, Guizhou Province, Yang Zhi, head of Huangping County, and relevant officials of the state and county governments went to Guizhou Huangping Jianfeng Cement Company to investigate and understand the project construction and production situation, and hope that the enterprises will develop as soon and promote regional economic development. Hu Hongwei, general manager of Huang Ping Jianfeng, and other members of the management team made a report on the overall work since the construction of the project started, and accompanied Zhou Zhou Zhou and his party to visit the production line site. In the central control room, Hu Hongwei to Zhou Zhou
2020
11-03
Zhang Xinyu, Vice Mayor of Jinhua City, hopes that Jianfeng Pharmaceutical will aim at cutting-edge science and technology to speed up the development of enterprises. On the afternoon of October 16, Zhang Xinyu, Vice Mayor of Jinhua City, and his party went to the construction site of Jianfeng Pharmaceutical's internationalization project of producing 2 billion pieces of solid preparations annually to conduct research. Accompanied by Huang Jinlong, deputy general manager of the group company and general manager of the pharmaceutical company, and Shen Quan, deputy general manager of the pharmaceutical company, Zhang Xinyu and his entourage visited the preparation workshop under construction and affirmed the civilized construction and safety management of the site. Huang Jinlong introduced the basic situation of the project to Zhang Xinyu and his party. Knowing that Jianfeng Pharmaceutical has introduced world-class production equipment and advanced technology to build a high-end preparation manufacturing platform in order to achieve industrial upgrading, Zhang Xinyu expressed his appreciation and encouraged Jianfeng Pharmaceutical to gain a foothold in China, aim at the world's cutting-edge technology, and accelerate the pace of enterprise development. Continuously enhance the overall competitiveness of the enterprise. (Wang xuesheng/Wen Zhou hengbin/photo)
2020
11-03